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ABSTRACT
Castration resistant-prostate cancer is largely impervious to feather hormonal 
therapy and hence the outlook for patients is grim. Here we use an approach to attach 
the recently discovered Achilles heel.  The experimental treatment established in this 
study is based on the recent discovery that it is the FABP5-PPARγ-VEGF signalling 
axis, rather than the androgen receptor pathway, played a dominant role in promoting 
the malignant progression of castration resistant prostate cancer cells. Treatments 
have been established in mice by suppressing the biological activity of FABP5 using 
a chemical inhibitor SBFI26. The inhibitor significantly suppressed the proliferation, 
migration, invasiveness and colony formation of PC3-M cells in vitro. It also produced 
a highly significant suppression of both the metastases and the primary tumours 
developed from cancer cells implanted orthotopically into the prostate glands of the 
mice. The inhibitor SBFI26 interferes with the FABP5-PPARγ- signalling pathway at 
the initial stage of the signal transduction by binding competitively to FABP5 to inhibit 
cellular fatty acid uptake. This avoids the fatty-acid stimulation of PPARγ and prevents 
it activating the down-stream regulated cancer-promoting genes. This entirely novel 
experimental approach to treating castration- resistant prostate cancer is completely 
different from current treatments that are based on androgen-blockade therapy. 
INTRODUCTION
Prostate cancer is an important cause of mortality 
in men, mainly in countries where a high dietary ratio of 
fatty acids is consumed [1]. Androgen deprivation therapy 
(ADT) is the first line treatment for advanced prostate 
cancer and it is initially effective.  However, in nearly all 
cases the disease eventually relapses within 2–3 years, 
with a lethal castration-resistant prostate cancer (CRPC); 
this cannot be effectively treated with ADT anymore [2]. 
Thus, identification of new targets for novel effective 
therapeutic approaches is urgently needed for the effective 
treatment of CRPC patients. The CRPC cells overexpress 
fatty acid synthase (FASN) and acetyl-CoA carboxylase 
(ACC) which are key enzymes involved in synthesis 
of fatty acids [3–5]. Fatty acids are not only active 
components of many biological processes, but also are 
essential signal molecules in pathways involved in prostate 
cancer progression, and hence can increase the risk of 
advanced prostate cancer [6, 7] and play an important role 
in carcinogenesis and metastasis of cancer cells [8].
Fatty acid-binding protein 5, or FABP5, is a 15kDa 
cytosolic protein binding with a high affinity to medium 
and long chain fatty acids [9]. After its crucial activity 
in promoting malignant progression in cancer cells 
was initially demonstrated [10, 11], increased FABP5 
expression in archival prostate cancer tissues is found to 
be significantly associated with a reduced patient survival 
time. Thus it is a valuable prognostic factor [12]. Moreover, 
investigations in the past few years established that there is 
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a novel fatty acid-initiated signalling pathway leading to 
malignant progression of prostatic cancer cells. Thus when 
FABP5 expression is increased, excessive amounts of fatty 
acids are transported into the nucleus, where they act as 
signalling molecules to stimulate their nuclear receptor 
PPARγ. The activated PPARγ then modulates expression 
of its down-stream regulatory genes which finally lead to 
enhanced tumour expansion and aggressiveness caused by 
an overgrowth of cells with increased angiogenesis and 
reduced apoptosis [13]. Recently, it was suggested that 
the FABP5-PPARγ-VEGF signalling transduction axis, 
rather than androgen receptor (AR)-modulated signal 
transduction pathway, that is the dominant signalling 
route in promoting malignant progression of CRPC cells 
[7]. Although the molecular mechanism involved in 
cancer-promoting activity of FABP5 has been extensively 
studied, it was not clear whether the CRPC can be treated 
by suppressing the biological activity of the oncogenic 
FABP5. The availability of a highly effective inhibitor is 
an important first step. Inhibition of FABP5 activity was 
shown to be effective for treatment of inflammatory and 
metabolic diseases by chemically synthesized inhibitors, 
e.g. BMS309403 [14–17]. Recently developed FABP5 
inhibitors, approximately 50% inhibitory effect of 
BMS309403, were originally used effectively as analgesic 
and anti-inflammatory agents in mice [18–20].  These 
included SBFI26 (α-truxillic acid 1-naphthyl mono-ester). 
SBFI26 was, in fact, the active component of a Chinese 
herbal medicine (Incarvillea sinensis) which was used to 
treat pain and rheumatism in humans in Chinese traditional 
medicine since hundreds of years ago [21, 22]. 
In a strategy to develop anti-inflammatory and 
anti-nociceptive reagents by targeting fatty acid protein 
anandamide transporters, SBFI26 was used to increase 
the brain anandamide levels and thus to produce analgesia 
effect [18, 19]. Although SBFI26 has been used as an 
inhibitor of FABP5 in anandamide transportation in brain, 
its possible effect on cancerous diseases was not known. 
In this study, we targeted the FABP5-related signalling 
pathway to treat CRPC in mice by using the SBFI26 to 
suppress the biological activity of FABP5 and to cut off 
the FABP5-related signalling transduction chain in CRPC 
cells. This is an entirely novel experimental approach 
to treat CRPC and is completely different from current 
treatments that are based on androgen-blockade therapy.
RESULTS
Identification of lead inhibitor of FABP5 from a 
group of chemical compounds
The inhibition constants (Ki) of 3 natural fatty acids 
(linoleic, oleic, palmitic acid) and 4 chemical compounds 
(SBFI26, SBFI19, SBFT27, SBFI31) which inhibited 
50% of the binding of fluorescent substrate DAUDA to 
wtrFABP5 were measured to identify the most potent 
inhibitor (Figure 1A).   The Kd of DAUDA- wtrFABP5 
was 1.86 ± 0.16 µM (Figure 1A/a). The calculated Ki 
(µM) values (Table B) of linoleic, oleic and palmitic acid 
were 1.58 ± 0.14, 1.89 ± 0.18 and 4.30 ± 0.4, respectively 
(Figure 1A/b, c, d). Thus linoleic acid had the strongest 
binding affinity for wtrFABP5. The most potent compound 
to bind wtrFABP5 was SBFI26 (Ki = 1.69 ± 0.15 µM), 
whose affinity was about 7.4- times higher than those of 
SBFI19 and SBFI27 (Ki = 12.54 ± 2.25 and 12.50 ± 2.07 
µM, respectively). The Ki of SBFI31 did not converge 
(Figure 1A/e, f, g, h). The binding affinity (Ki) of the lead 
compound (SBFI26) for wtrFABP5 was similar to that of 
the best- binding fatty acid (linoleic acid). DAUDA assay 
was performed to ascertain the degree of displacement 
of DAUDA from wtrFABP5 by the chemical inhibitors 
and the results are shown in Figure 1C. The relative level 
of fluorescence intensity of wtrFABP5 with DAUDA 
was 2.65 ± 0.14. This was reduced to 1.37 ± 0.07, 1.68 
± 0.09 and 1.80 ± 0.08 after adding linoleic, oleic and 
palmitic acids, respectively, to the complex. After SBFI26, 
SBFI19, SBFT27, and SBFI31 were added to the complex, 
the intensity was reduced to 1.48 ± 0.06, 2.33 ± 0.08, 
1.95 ± 0.17 and 2.58 ± 0.79, respectively. Linoleic acid 
and SBFI26 produced highly significant reductions in 
fluorescence intensities (Student’s t test, P < 0.0001). 
Inhibitory effect of SBFI26 on malignant 
characteristics of PC3-M cells
Results of the inhibitory effect of SBFI26 on 
malignant characteristics of the PC3-M prostate cancer 
cells are shown in Figure 2.  Cytotoxicity tests showed 
that treatment with SBFI26 significantly suppressed 
viability of PC3-M cells in a concentration- dependent 
pattern. Maximum suppression was produced at 100 µM 
for SBFI26; further increase in doses did not produce any 
further significant suppression. When treated with this 
optimal dose, cell numbers were significantly reduced 
by 26% (Student’s t test, P < 0.001) (Figure 2A). When 
tested using a MTT assay, 100 µM SBFI26 significantly 
reduced the proliferation rate of PC3-M cells by 17-times 
(Student’s t test, P < 0.0001) (Figure 2B). When tested 
in a cell migration assay (Figure 2C), treatments with 
100 µM SBFI26 produced only 19% reduction in wound 
size in 24h. This treatment significantly suppressed 
the migration rates of PC3-M cells (Student’s t test, 
p < 0.0001), leading only to small changes in wound gaps 
for the treated group compared to an almost complete gap 
closure (94%) for the control (Figure 2D). When tested 
in an invasion assay, the mean numbers of invaded cells 
from the control and the PC3-M cells treated with SBFI26 
were 22 ± 3 and 1 ± 1, respectively, representing a highly 
significant suppression of invasion by 95.5% (Student’s 
t test, P < 0.0001) (Figure 2E). Further tests in soft agar 
showed that the number of colonies formed after 2 weeks 
by control PC3-M cells and PC3-M cells treated with 
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Figure 1: Detection of binding affinities of 4 candidate compounds to wtrFABP5 with DAUDA displacement assay to 
identify the lead chemical inhibitor of FABP5. (A) Chart records of binding affinity analysis of 3 different fatty acids and 4 different 
candidate chemical inhibitors of FABP5. a) Titration curve of DAUDA binding to wtrFABP5. Fixed amounts (3 µM) of wtrFABP5 were 
incubated with increasing concentrations of DAUDA (0.4–3 µM). For calculation of the dissociation constant Kd values, the excitation 
and emission used was 345 and 530 nm, respectively and the fluorescence data was normalized to the peak fluorescent intensity for each 
experiment and data of samples without protein was subtracted. The data was fitted by nonlinear regression techniques using GraphPad 
Prism software to a saturation binding curve model to estimate the apparent dissociation constant (Kd) and maximal fluorescence intensity 
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SBFI26 were 124 ± 18 and 0, respectively, representing 
a highly significant inhibition by 100% (Student’s t test, 
p < 0.0001) (Figure 2F). 
Effect of SBFI26 on tumourigenicity and 
metastatic ability of PC3-M cells in mouse 
prostate gland 
PC3-M cells were stably transfected with the luciferase 
vector and the 2 transfectant colonies that generated high 
bioluminescence signals were picked and named PC3-M-
Luc8 and 21, respectively (Figure 3A). Further measurement 
with the IVIS image system showed that PC3-M-Luc8 
produced the highest level of bioluminescence signal (Figure 
3B) and there was a correlation between total flux and the 
number of labelled cells (R2 = 0.98) (Figure 3C).  Luciferase-
labelled PC3-M-Luc8 were implanted orthotopically into the 
dorsolateral side of the prostate of each of 2 groups of nude 
mice that were then intraperitoneally injected daily with PBS 
and SBFI26, respectively, for 25 days. At day 25, there was 
a massive decrease in bioluminescence signal (p/sec/cm2) 
in SBFI26 (6.66 × 108) treated group in comparison with 
the control (31.5 × 108). On the basis of bioluminescence, 
our results showed about 4.9-fold suppression in tumour 
masses by SBFI26 over those of control group (Student’s 
t test, P < 0.0001) (Figure 3D). In the control group, 7/7 
(100%) mice produced metastases. In the group treated with 
SBFI26, 4/8 (50%) of mice produced visceral metastasis. A 
suppression of 50% in metastasis incidence was seen when 
compared to the control group (Figure 3E). Histological 
staining showed that all mice developed metastases in the 
control group, mainly in the liver and lung.  In the SBFI26 
treated group, half of the mice developed liver metastases 
with no metastasis in the lung. One representative stained 
slide from each group/organ is shown in Figure 3F.    
SBFI26 inhibited tumourigenicity of PC3-M cells 
in nude mice in a similar way to PPARγ antagonist 
PC3-M cells were inoculated into the right flank of 
nude mice and the FABP5 inhibitor SBFI26 was injected 
subcutaneously into the flank of the mice to compare its 
anticancer effect with that of PPARγ antagonist (Figure 4). 
Although remarkable suppression of tumour growth was 
found in mice treated with the inhibitor (Figure 4B), 
no significant difference in treatment effect was found 
when inhibitor was applied from day 1 or from day 7 
after the inoculation.  On termination, average volumes 
of tumours in the group treated with SBFI26 was 302 
± 86 mm3, compared to 627 ± 120 mm3 in the control 
group; significant suppressions of 52% (Student’s t test, 
p < 0.001) (Figure 4A and B). When tumours were 
weighed on termination, the difference between control 
and treated group was similar to that measured by tumour 
volume (Figure 4C). To study possible suppression by 
PPARγ antagonist GW9662, mice were injected with 
PBS and with GW9662, respectively, from day 7 after 
inoculations (Figure 4E). Compared to the average size 
of tumours (774 ± 202 mm3) in control group, the average 
size of tumours in the group treated with GW9662 was 
reduced to only 252 ± 84 mm3, a highly significant 
suppression by 67% (Student’s t test, p < 0.0001) 
(Figure 4D). When tumour weight was measured at 
autopsy, the difference between control and the treated 
group was similar to that measured by tumour volume 
(Figure 4F).
SBFI26 inhibited fatty acid uptake of FABP5 in 
PC3-M cells 
To investigate possible effect of FABP5 inhibitors 
on fatty acid uptake of PC3-M cells, a fatty acid uptake 
assay was performed using red fluorescence-labelled 
fatty acid BODIPY (Figure 5). Unstained cells (without 
BODIPY) were present in M1 zone (Figure 5A) and 
BODIPY stained cells were present in M2 zone after 
30min incubation (Figure 5B). In contrast to benign 
PNT2, significantly more than 20% and 25% of cells 
took up fatty acid in moderately malignant 22RV1 and 
highly malignant PC3-M (Student’s t test p < 0.01 and p 
< 0.001) cells, respectively. Levels of fatty acid uptake 
between benign PNT2 and weakly malignant LNCaP 
cells were similar (Figure 5C). The effect of increasing 
concentration of SBFI26 on fatty acid uptake in PC3-M 
(Bmax). The apparent dissociation constant (Kd) for DAUDA to wtrFABP5 was calculated to be 1.86 ± 0.16 µM. (b, c, d) Inhibition constant 
Ki (binding affinity) of Linoleic, Oleic and Palmitic acids binding to wtrFABP5. The Ki was measured to determine the potency of binding 
of these fatty acids with wtrFABP5 by evaluating their ability to displace DAUDA. The data were collected by displacement of 2 µM 
DAUDA from 3 µM wtrFABP5 in the presence of different concentrations of each fatty acid (0.5–20 µM). All data were fitted to a one site 
binding affinity model by non-linear regression techniques using GraphPad Prism software to estimate the binding affinity. The Ki of each 
ligand was determined using the equation Ki = IC50/1+ (DAUDA concentration /Kd). The binding affinity of Linoleic acid (Ki = 1.57 µM) 
was higher than that of Oleic and Palmitic acids (Ki = 1.88 and 4.30 µM, respectively). (e, f, g) Inhibition constant Ki of SBFI26, SBFI19, 
SBFI27, and SBFI31 to wtrFABP5. The data were collected by displacement of 2 µM DAUDA from 3µM wtrFABP5 in the presence of 
different concentrations (0.5–20 µM) of each chemical compound. All data were fitted to a one site binding affinity model by non-linear 
regression techniques using GraphPad Prism software to estimate the binding affinity. The binding affinity of SBFI26 (Ki =1.68 µM) was 
the highest amongst the 4 compounds. (B) Ki values of 3 different fatty acids and 4 different candidate chemical inhibitors. (C) Fluorescence 
intensity of displacement of 2 µM DAUDA binding from 3µM wtrFABP5 in the presence of 10 µM of 3 different fatty acids and 4 different 
candidate chemical inhibitors. The value of fluorescence intensity produced by the buffer and DAUDA plus wtrFABP5 was set as control. 
The results (mean ± SE) were obtained from 3 separate experiments (2-tailed unpaired Student’s t test, ***P < 0.0001). 
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Figure 2: Inhibitory effect of SBFI26 on proliferation, migration, invasion and anchorage-independent growth of 
the androgen-independent PC3-M prostate cancer cells. (A) Determination of the optimal inhibitory concentration of SBFI26 
at which the maximum suppression of cell growth is achieved. MTT assay was performed to measure the viable PC3-M cell numbers of 
the control (untreated) and those treated with different concentrations of SBFI26 for 24 h. (B) Inhibitory effect of 100 µM SBFI26 on 
proliferation of PC3-M cells over the 7day experimental period. (C) Representative photos of the wound healing assay. PC3-M cells were 
grown in 6-well plates to form a monolayer. Scratches were made using 1 mL sterile pipette tip. Cell migration capacity was measured by 
the reduction in wound size in control (1) and in cultures treated with 100 µM SBFI26 (2) observed at 0, 12 and 24 hours after treatment. 
The scale bar is 250 µm. (D) Average wound sizes (µm) of the control PC3-M and cultures treated with 100 µM SBFI26 observed at 0, 
12 and 24 hours after treatment. Data was collected by measuring image of the wound space and analyzed by ImageJ software (National 
Institutes of Health). (E) Number of invading cells from the control PC3-M cells (1) and cultures treated with 100 µM SBFI26 (2) for 24 h 
after different treatments. Results (mean ± SE) are obtained from three separate measurements. Scale bar is 250 µm. (F) Colonies produced 
by the control PC3-M cells (1) and cultures treated with 100 µM SBFI26 (2) in soft agar 2 weeks after the different treatments. Results 
(mean ± SE) are obtained from three separate plates in each treatment. The inserted picture was a representative plate from each of the 3 
treatments. All in vitro results were subjected to 2-tailed unpaired Student’s t test and *P < 0.05; **P < 0.001; ***P < 0.0001.
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Figure 3: Inhibitory effect of SBFI26 on tumorigenicity and metastatic ability of PC3-M cells implanted orthotopically 
into the prostate gland of the nude mouse. (A) Establishment of stable PC3-M colonies expressing strong bioluminescence signals 
by pGL4.50 [luc2/CMV/Hygro] vector transfection.  Relative light units (mean ± SE) of the PC3-M parental cells and 33 colonies derived 
from PC3-M cells were obtained from 3 separate measurements. Individual colonies were isolated by ring cloning and 3 colonies that 
stably-expressed the highest bioluminescence signals were identified using D-luciferin (Promega) with a Varioskan Flash Reader (Thermo 
Scientific). (B) Detailed observation of the intensities of the bioluminescence images of the serially-diluted (20-100000) parental PC3-M 
cells and 3 representative PC3M-Luc transfectants. Association of the luminescence intensity with the number of cells was assessed by an 
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cells was determined using a fixed concentration of 
BODIPY (Figure 5D). When inoculated with SBFI26, 
cellular fatty acid uptake into PC3-M cells was reduced 
from 92.9% in the control in a dose-dependent manner, 
the maximum reduction with 100 µM was 67.7% 
(Figure 5E). 
SBFI26 inhibited PPARγ activation 
The effect of FABP5 inhibitor SBFI26 on levels 
of biologically active PPARγ or phosphorylated PPARγ 
(p-PPARγ1 and p-PPARγ2) in benign and malignant 
prostate epithelial cells is shown in Figure 6.  Western 
blot detected a PPARγ band at 55kDa in most of the cell 
lines used (Figure 6A). When the level of PPARγ in PNT2 
was set at 1.0, relative levels of PPARγ in LNCaP, 22RV1, 
DU145, PC3 and PC3-M were 0.70 ± 0.03, 0.02 ± 0.01, 
0.22 ± 0.001, 0.4 ± 0.0 and 0.64 ± 0.04, respectively 
(Figure 6B). When Western blot was used to detect 
p-PPARγ, 2 bands representing isoforms of p-PPARγ1 
and p-PPARγ2 were found at 54 and 57kDa, respectively 
(Figure 6C). If levels of p-PPARγ1 and p-PPARγ2 in 
PNT2 were set at 1 and 1, relative levels in LNCaP, 
22RV1, DU145, PC3 and PC3-M were 9.54 ± 1.81 and 9.5 
± 0.5; 25.4 ± 1.8 and 47.0 ± 1.7; 26.99 ± 1.72 and 85.5 ± 
14.5; 12.08 ± 1.8 and 30 ± 5; and 21.99 ± 2.63 and 80 ± 5, 
respectively (Figure 6D).  Levels of p-PPARγ, particularly 
p-PPARγ2, were significantly increased in all malignant 
cell lines (Student’s t test, p < 0.001). To investigate the 
effect of FABP5 inhibitor SBFI26 on p-PPARγ, PC3-M 
cells were treated with SBFI26, GW9662 and PPARγ 
agonist Rosiglitazone for 24 hours (Figure 6E). If levels 
of p-PPARγ1 and p-PPARγ2 in untreated cells were 
set at 1 and 1, the levels after treatment with SBFI26 
and GW9662 were reduced significantly by 44% and 
46%; 52% and 51%; respectively (Student’s t test, p < 
0.001). However, in those cells treated with rosiglitazone, 
significantly increased levels of both p-PPARγ isoforms 
were observed (Student’s t test, p < 0.01) (Figure 6F). 
When treatments with wtrFABP5, SBFI26 were tested in 
androgen-sensitive 22RV1 cells (Figure 6G), wtrFABP5 
significantly increased levels of both p-PPARγ1 and 2 
(Student’s t test, P < 0.01) (Figure 6H). But treatment 
with the inhibitor SBFI26 suppressed the levels of both 
p-PPARγ isoforms.
DISCUSSION
Since it was discovered that prostate cancer cell 
growth is dependent on the promoting effect of male 
hormone supplied through peripheral blood circulation 
[23], ADT targeting AR and circulating androgen has 
been the main therapeutic method to treat prostate cancer 
patients during the past 4 decades. However, the disease 
relapses within a period of time with a more aggressive 
form, called androgen-independent prostate cancer 
or castration resistant prostate cancer which does not 
respond to ADT effectively anymore. The conversion of 
androgen-dependent cancer cells to androgen independent 
CRPC cells is a fundamental change and the molecular 
mechanisms involved in this change is not fully known. 
Currently, there are a number of different hypotheses on 
how the androgen-dependent cells were transformed to 
androgen-independent cells. The main theory is that the 
biological sensitivity of AR is amplified after the first 
round of ADT to such an extent that even micro-quantities 
of remaining hormone in peripheral blood can still promote 
the malignant progression of CRPC cells [24]. Thus further 
ADT on CRPC was a general clinical practice.  However, 
some opposite opinions to this practice were proposed 
recently [25]. Our previous work suggested that AR 
may not be relevant to malignant progression of CRPC 
and that targeting FABP5- PPARγ-VEGF axis, rather 
than the AR-mediated signalling pathway, which was 
gradually replaced by the FABP5-related pathway as the 
reduced androgen-dependency, could be a more effective 
way for CRPC treatment [7]. Here for the first time, we 
targeted the oncogenic FABP5 and its related signal 
transduction pathway and successfully used a chemically-
synthesized FABP5 inhibitor to treat CRPC in nude mice 
by suppressing the biological activity of FABP5.
A group of 4 chemical compounds capable 
of suppressing the transportation of anandamide by 
FABP5, was originally used as anti-nociceptive and anti-
inflammatory agents. They worked by increasing levels 
of brain anandamide transported by FABP5 and produced 
analgesia [18, 19]. The DAUDA displacement assay 
showed that 3 of these 4 compounds had the ability to 
bind to wtrFABP5, just as well as the 3 fatty acids tested 
(Figure 1). The dissociation constant (Kd) for titration 
of DAUDA with wtrFABP5 was within the range of 
the other FABPs [26]. Although Linoleic acid had the 
IVIS imaging system (Perkin Elmer). The color bar on the right indicates the signal intensity range (photons/second/cm2). (C) Correlation 
between the bioluminescence flux intensity (photons/second) and the number of cells derived from 3 different PC3-M-Luc colonies. 
(D) Whole body tumor bioluminescence flux produced by each group of nude mice after orthotopic implantation of luciferase-labelled 
PC3-M cells and treated with PBS (control), SBFI26 (1 mg/kg) for 25 days. Values were plotted as mean ± SE (error bars) (n = 8); the 
difference between the control and each of the testing groups was assessed by two-tailed unpaired Student’s t test ***P < 0.0001. (E)
Ventral bioluminescence images of primary tumors and metastases in all groups of experimental mice 25 days after treatment. The color 
bar on the right indicates the signal intensity range (photons/second/cm2). (F) Representative photomicrographs of detection of liver and 
lung metastases (arrows) from mice which received injection of PBS (1) and SBFI26 (2). Sections of tissues were stained with H&E. 
Magnification, ×10 and scale bar is 100 µm. All animal work was performed in accordance with UKCCCR guidelines under Home Office 
License PPL40/2963.
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Figure 4: Effect of SBFI26 or GW9662 on tumorigenicity in prostate cancer xenograft mice. (A) Average volume of tumors 
produced by each group of male nude mice after subcutaneous inoculation of PC3-M cells (2 × 106) and treated with PBS (control) or SBFI26 
(1 mg/kg) for 31 days; started on day 1 and day 7 after inoculation. Values are plotted as mean ± SE (error bars) (n = 8); difference between 
the control group and the experimental groups were assessed by 2-tailed unpaired Student’s t test, **P < 0.001. (B) Representative mouse 
and its corresponding tumors from control (1) and SBFI26 treated (2) groups. (C) Average weight (mg) of tumours from control and SBFI26 
treated groups of mice. Values were plotted as mean ± SE (error bars). The differences between the control and the experimental groups were 
assessed by 2-tailed unpaired Student’s t test **P < 0.001. (D)  Average volume of tumors produced by each group of male nude mice after 
subcutaneous inoculation with PC3-M cancer cells and treated with PBS (control) and PPARγ antagonist (GW9662;1 mg/kg) for 31 days. 
Values were plotted as mean ± SE (error bars) (n = 5); differences between the control and the experimental groups were assessed by 2-tailed 
unpaired Student’s t test ***P < 0.0001. (E) Representative mouse and its corresponding tumor from each of the control (1) and GW9662 (2) 
groups. (F) Average weight (mg) of tumours in the control and experimental groups of mice. Values were plotted as mean ± SE (error bars). 
Differences between the control and the experimental groups were assessed by 2-tailed unpaired Student’s t test ***P < 0.0001.
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highest binding ability amongst the 3 fatty acids, SBFI26 
inhibited the highest FABP5 binding ability amongst the 
4 compounds, and thus was identified as the lead inhibitor 
of FABP5 for suppressing its fatty acid-binding ability. 
Androgen-independent prostate cancer cell line PC3-M, 
expressing high levels of FABP5 and PPARγ [7, 27] was 
an extremely malignant and metastatic cell line.  When 
the biological function of FABP5 was inhibited using 
SBFI26, significant anti-proliferation, anti-invasive, anti-
migration and anti-anchorage-independent growth in vitro 
using PC3-M cell line was observed (Figure 2). SBFI26 
as a lead inhibitor of FABP5 showed efficient anti-tumour 
roles in the mouse model for primary tumours implanted 
in the prostate gland (by 4.9- fold) and inoculated in the 
flank (by 52%). Compared to the control group, in which 
all mice (100%) developed metastases, SBFI26 treatment 
suppressed metastases in half of the mice of the treated 
group (50%). These results suggest that SBFI26 can be 
used as an anti-tumour agent to treat CRPC.
Increased levels of FABP5 play a crucial role 
in promoting malignant progression in CRPC cells by 
binding and transporting increased amounts of fatty 
acids to stimulate PPARγ [7, 13, 28, 29]. It is known that 
increases in uptake of fatty acids will contribute to the 
switch in energy production from aerobic to anaerobic 
sources as well as the downstream effect of increased 
production of VEGF to stimulate angiogenesis. These 
changes are induced by increased levels of FABP5 and 
may contribute to the amelioration of the effects of 
chronic hypoxia which is known to occur as prostate 
cancer develops [30, 31]. In this work we showed that 
the treatment of PC3-M cells with the PPARγ antagonist, 
GW9662, produced a better suppression of tumour 
growth to that obtained by SBFI26 (Figure 4).  This result 
suggests that the suppressive mechanisms of the inhibitor 
may be related to the FABP5- PPARγ- signal transduction 
pathway [7]. In confirmation, we showed not only the fatty 
acid uptake was increased with increasing malignancy of 
prostate cancer cells, but also that SBFI26 produced a 
remarkable reduction in fatty acid uptake into PC3-M cells 
(Figure 5). These results suggest that SBFI26 may be a 
competitive inhibitor for FABP5 and hence prevent intra- 
and extra-cellular fatty acids from being transported into 
the cytoplasm. The reduced fatty acid uptake produced by 
SBFI26 may result in a remarkable reduction or cessation 
of the stimulation of PPARγ by fatty acids. Thus PPARγ 
may no longer be able to upregulate the down-stream 
cancer-promoting genes, such as VEGF, and to suppress 
apoptosis [32, 33]. 
Our recent study showed that the FABP5-PPARγ-
VEGF signalling transduction axis, not the androgen 
receptor-initiated pathway, is a dominant route for 
transduction of malignant signals in CRPC cells [7]. In this 
axis, the role of PPARγ is essential. Thus, although the total 
PPARγ expressed in the malignant cell lines was not higher 
than that in the benign PNT2 cells (Figure 6A, 6B), both 
biologically-activated PPARγ isoforms (or phosphorylated 
PPARγ) p-PPARγ1 and p-PPARγ2 [34, 35] increased 
with increasing cellular malignancy (Figure 6C, 6D). The 
p-PPARγ isoforms in PC3-M cells, which were expressed 
in high levels and were further increased by rosiglitazone 
(PPARγ agonist), their levels had greatly reduced by 
treatments with SBFI26 and GW9662 (Figure 6E, 6F). 
These results suggest that SBFI26 may act as an inhibitor 
to block the stimulation of fatty acids transported by wild 
type FABP5 and hence prevent activation of PPARγ. PPARγ 
is a fatty acid receptor localised in the nuclear membrane 
[36–38]. Thus the inhibition of phosphorylation by SBFI26 
is likely to cause inhibition of fatty acid uptake. It has been 
suggested that SBFI26 is a weak agonist of PPARγ [18]. 
Since SBFI26 suppressed fatty acid uptake by replacing fatty 
acids which bind to FABP5, it is possible that some SBFI26 
may be delivered to activate PPARγ in a much weaker 
way than with the fatty acids. This may be the reason why 
SBFI26 produced a slightly lower degree of suppression in 
tumourigenicity and metastasis than GW9662. Although 
SBFI26 did not produce a complete inhibition of CRPC, its 
therapeutic effect was highly significant.
PPARγ  is highly expressed in adipose tissue and 
plays an important role to regulate adiposity and insulin 
sensitivity [39]. Two biologically active isoforms of 
PPARγ, PPARγ1 and PPARγ2, are expressed in human 
tissues [34, 35]. The potential of using PPARγ as a direct 
target for cancer treatment has been widely investigated 
during the past decade but still remains debatable.  Both 
PPARγ agonist and antagonist have shown some anticancer 
effect through PPARγ-dependent and -independent 
pathway [40, 41]. However, there are safety concerns: 
side effects, including dose limited side effects linked 
to PPARγ drug treatments, increased the risk of cardiac 
Figure 5: Fatty acid uptake of different prostate epithelial cell lines and inhibitory effect of SBFI26 in PC3-M cells. 
(A) Representative histograms for unstained PNT2, LNCaP, 22RVI and PC3-M cells without adding BODIPY-labelled fatty acid. The marker 
M1 highlights negative peaks of the subclass control. (B) Representative histograms for fluorescence of stained PNT2, LNCaP, 22RVI and 
PC3-M cells 30min after adding BODIPY-labelled fatty acid and the marker M2 is placed to the right of M1 to highlight positive events 
(total percentage of cells with BODIPY-labeled fatty acid). (C) Percentages of cells taking up BODIPY-labelled fatty acid from different 
prostate epithelial cell lines. (D) Representative histograms for fatty acid uptake of PC3-M cells at a fixed concentration of BODIPY-
labelled fatty acid with different concentrations of SBFI26. M1, unstained cells; M2, stained cells. (E) Percentages of cells with fatty acid 
uptake from PC3-M control (untreated) and those treated with different concentrations of SBFI26 for 30min with a fixed concentration of 
BODIPY-labelled fatty acid. Fluorescence intensity of each cell line was measured with an EPICS XL Cytometer (Beckman) at 570 nm 
and data analysis was performed with SYSTEM II™ Software. Values were plotted as mean ± SE (error bars). The differences between the 
control and the experimental groups were assessed by 2-tailed unpaired Student’s t test.  *P < 0.01; **P < 0.001.
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failure and potential carcinogenicity in rodents [42]. In 
addition, PPARγ agonist inhibitors have been shown to 
suppress cell growth and induce apoptosis of prostate 
cancer cells by both PPARγ-dependent (genomic) and - 
independent (non-genomic) signalling pathways. Thus 
it remains unclear whether the non-genomic effects are 
essentially on PPARγ pathways [43]. GW9662 is a potent, 
irreversible and selective PPARγ antagonist, and it has 
been reported to inhibit growth of human breast cell line 
in a PPARγ- independent manner [44]. However, the 
results from another study indicated that GW9662 has 
a protective role in cancer by blocking cannabinoids-
induced apoptosis in xenograft-induced tumours in mice 
[45]. It was found that GW9662 has a significant effect 
on adipose tissue weight and glucose metabolism in 
vivo. If GW9662 is administrated continuously for a long 
time, it can reduce weight and suppress any increase in 
the amount of visceral adipose tissue [46]. In addition, 
GW9662 upregulates the expression of several genes 
associated with the transcription, processing, splicing and 
translation of RNA [47]. Although our results in this study 
showed that GW9662 produced significant reduction in the 
sizes of tumours developed from cancer cells inoculated 
subcutaneously in flanks of the mice, using GW9662 as a 
therapeutic reagent is hardly possible because of its none-
specificity. In fact, due to the versatile nature of PPARγ in 
its biological function, targeting PPARγ directly for cancer 
treatment is also difficult to achieve. 
Previous work suggested that the dependency of 
the prostate cancer cells on the FABP5-related pathway 
was gradually increased with a correspondingly reduced 
dependency on the AR-initiated pathway until the 
former became completely dominant [7]. In this study, in 
androgen-responsive, moderately-malignant 22RV1 cells, 
SBFI26 produced a reduction in both PPARγ activated 
isoforms by an average of 33.5% (Figure 6G, 6H). This 
level of reduction was much lower than that caused by 
SBFI26 in the androgen-independent, highly malignant 
PC3-M cells (average reduction was about 50%). These 
results suggest that the proportion of activated PPARγ 
regulated by the FABP5-related pathway was much higher 
in PC3-M cells than that in 22RV1 cells, a result which 
suggests that treatment by suppression of the FABP5-
pathway is more effective in CRPC cells. This supports the 
previous finding that ADT would lose its effect gradually 
as the cancer cell become more independent of androgen 
for growth and is consistent with the eventual loss of AR 
receptor in most advanced cancers [7, 25].  
In summary, we have targeted the FABP5-PPARγ 
signalling pathway by suppressing the biological activity 
of oncogenic FABP5 so that the signalling molecules fatty 
acids cannot be passed to PPARγ.  Thus this signalling 
axis is ceased to functioning due to the lack of fatty acids 
stimulation. Therefore, the FABP5 inhibitor SBFI26 
supressed the malignant progression of CRPC by cutting 
off the FABP5-related signalling transduction chain at the 
initial stage and it may be a candidate reagent for a CRPC 
treatment.
MATERIALS AND METHODS
Cell lines and chemical inhibitors
The benign cell line PNT2 [48], highly malignant, 
androgen-independent cell lines DU145 [49], PC3 [50] and 
PC3-M [51], the moderately malignant, androgen-responsive 
cell line 22RV1 [52], and the weakly malignant cell line 
LNCaP [53] were cultured and maintained in 1640 medium 
(Invitrogen) supplemented with 10% FCS (Biosera), 100 U/
mL penicillin and 100 μg/mL streptomycin (Invitrogen). 
For LNCaP cells, 100 μg/mL sodium pyruvate (Sigma) was 
added to the culture medium. Chemically synthesized FABP5 
inhibitors used in this study, including SBFI26 (cat# 8009-
2334), SBFI19 (cat# 5511-0235), SBFI27 (cat# 8009-7646) 
and SBFI31 (cat# C075-0064) were purchased from ChemDiv, 
dissolved in DMSO, and stored at –20˚C. The working 
concentration of DMSO for all in vitro assays was 0.1% (v/v). 
Ligand binding assay
The fatty acid-binding ability of wtrFABP5 was 
examined by using the DAUDA displacement assay 
which used fatty acids and different chemical compounds 
to replace the fluorescently labelled fatty acid analogue 
DAUDA (Cayman). The dissociation constant (Kd) 
of wtrFABP5 was measured by titrating different 
concentrations of DAUDA (0.4–3 µM) to a solution of 
3 µM wtrFABP5 in PBS. For calculation of Kd values, 
the excitation and emission wavelengths used were 
345 and 530 nm, respectively. For each experiment, the 
fluorescence data were normalized to the peak fluorescent 
intensity [54], and then subtracted from the data of 
samples without protein. The data were fitted by nonlinear 
regression using GraphPad Prism software to a saturation 
binding curve model to estimate the apparent dissociation 
constant (Kd) and maximal fluorescence intensity (Bmax). 
The inhibition constant (Ki) was measured to determine the 
potency of different fatty acids (Linoleic, Oleic, Palmitic 
acid) (Sigma) and different inhibitors (SBFI26, SBFI19, 
SBFI27, and SBFI31 to wtrFABP5 by their ability to 
displace DAUDA. Three µM wtrFABP5 was incubated 
with 2 µM DAUDA in PBS in the presence or absence 
of each fatty acid or each chemical inhibitor in different 
concentrations (0.5–20 µM). Loss of fluorescence intensity 
was measured with Varioskan Flash and the data were fitted 
by nonlinear regression using GraphPad Prism software to 
a one site binding affinity model to estimate the binding 
affinity. The Ki of each ligand was determined using the 
equation Ki = IC50/1+ (DAUDA concentration /Kd). The 
lead compound and the best fatty acid that produced the 
highest binding affinity were then added to the assay at 
10 µM, and tested in triplicate to confirm their activity. 
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Figure 6: Effects of SBFI26 on levels of biologically active PPARγ or phosphorylated PPARγ (p-PPARγ1 and
 
p-PPARγ2) 
in prostate cancer cells. (A) Western blot of PPARγ expression in benign and malignant prostate epithelial cells. (B) Quantitative 
assessment of levels of PPARγ in benign and malignant prostate epithelial cells. The level of PPARγ in the benign prostate PNT2 cells was 
set at 1; levels in the other prostate cell lines were obtained by comparison with that in PNT2. (C) Western blot analysis of p-PPARγ1 and 
p-PPARγ2 in benign and malignant prostate epithelial cells. (D) Quantitative assessment of the levels of p-PPARγ1 and p-PPARγ2 in prostate 
cells. Levels of p-PPARγ1 and 2 in benign PNT2 cells were set at 1; levels in the other prostate cells were obtained by comparison with those 
in PNT2. (E) Effect of 24 h treatments with SBFI26, PPARγ antagonist (GW9662) and PPARγ agonist (Rosiglitazone on levels of p-PPARγ1 
and 2 in PC3-M cells. (F) Quantitative assessment of p-PPARγ1 and 2 levels in PC3-M cells after treatments with SBFI26, GW9662 and 
Rosiglitazone. Levels of both p-PPARγ1 and 2 in untreated PC3-M cells were set at 1; levels in the other treated cells were obtained by 
comparison with those in untreated PC3-M. (G) Effect of 24 h treatments with wtrFABP5 and SBFI26 on levels of p-PPARγ1 and 2 in 22RV1 
cells. (H) Quantitative assessment of levels of p-PPARγ1 and 2 in 22RV1 cells. Levels of both p-PPARγ1 and 2 in the control were set at 1; 
levels in the other treated cells were obtained by comparison with those in controls. For each Western blot, anti-β-actin was incubated with 
the same blot to normalize for possible loading errors. Results (mean ± SE) were obtained from 3 separate experiments and the differences 
between the control and the treatments in each experiment were assessed by 2-tailed unpaired Student’s t test. *P < 0.05; **P < 0.001. 
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Cell viability and proliferation assay
PC3-M cells (5 × 104) were plated in triplicate in 96 well 
plates and incubated overnight. Cells were treated with different 
concentrations of SBFI26 (25–125 µM) for 24 h. Cell viability 
was assessed using MTT assay, as described previously [12]. 
The anti-proliferative effect of the best concentration for 
SBFI26 was determined after 6 days of treatment. 
Migration assay
Wound healing migration assay was carried out 
to evaluate the effect of SBFI26 on the migratory rate 
of PC3-M cells. Wounds were generated by scratching 
the monolayer cells with a blue pipette tip. The floating 
cells were removed by washing with PBS and inhibitors 
were added to the culture medium. The wound was 
photographed under the microscope at 0, 12 and 24 h 
after treatment and the wound widths were assessed by 
quantitative analysis using ImageJ software.
Invasion assay
PC3-M cells in serum-free medium were seeded 
in the upper Boyden chamber (BD Biosciences) in 
triplicate at a density of 2.5 × 104 cells per well in serum-
free medium. Complete medium was added to the lower 
chambers. After 3 hours of incubation, 100 µM SBFI26 
was added to the upper chambers. After 24 h of incubation, 
cells that invaded the lower chambers were stained with 
crystal violet and counted with a cell counter.
Soft-agar assay
Low melting agarose was seeded in 6-well plates 
and 5 × 104 cells/well layered on agar, followed by 200 µl 
of medium alone or medium with FABP5 inhibitor SBFI26. 
Colonies larger than 300 µm in each well were counted 2 
weeks later in a similar way to that described previously [12].
Nude mouse assay to test tumorigenicity and 
metastasis
PC3-M cells were transfected with the pGL4.50 
[luc2/CMV/Hygro] vector (Promega) using FuGene 
HD transfection reagent (Promega) following the 
manufacturer’s instructions. Individual colonies were 
isolated by ring cloning and 3 colonies that stably-
expressed the highest bioluminescence signals were 
identified using D-luciferin (Promega) with a Varioskan 
Flash Reader (Thermo Scientific). Association of the 
luminescence intensity with the number of cells was 
assessed by an IVIS imaging system (Perkin Elmer). Cells 
(5 × 105) from PC3-M- luc2 colony were suspended in 
30 µL PBS and orthotopically implanted into the dorsal 
prostate of 33 male Balb/c nude mice (Charles River, UK) 
(8–10 weeks old), as described previously [55]. One week 
later, tumour-bearing mice were divided into 2 groups 
(8 each) and subjected to the following intraperitoneally 
injections: 1) control with PBS; 2) SBFI26, 1mg/kg. 
Injections were repeated every two days for 25 days and 
the metastatic loci were monitored weekly using the IVIS 
after mice were subcutaneously injected with D-luciferin 
(150 mg/kg). Bioluminescence images was analysed 
using the Living Imagine software (Xenogen) and the 
measurement recorded was based on total photons/second 
(p/s) within each defined region of interest. 
Nude mouse tumorigenecity assay
PC3-M cells (2 × 106) in 200 µL PBS were 
subcutaneously injected into the right flank region of the 
mouse (6–8 week old) to test the suppressive effect of the 
inhibitors on tumorigenicity. In the first round, 3 groups 
of mice (8 each) were used: 1) control with PBS; 2) 1mg/
kg SBFI26, injected from the 1st day after cell inoculation; 
3) 1mg/kg SBFI26, injected from the 7th day after cell 
inoculation. In the second round, 2 groups of mice (5 each) 
were used and at 7 days after the cell inoculation, each 
group was subjected to different intra-tumoural injections: 
1) control with PBS; 2) PPARγ antagonist (GW9662, 1mg/
kg) (Sigma). The injections were repeated every 2 days for 
30 days, tumour size was measured every 3–4 days and 
the volume calculated by the formula of L× W×H×0.5236 
[56]. Work was performed in accordance with UKCCCR 
guidelines under Home Office License PPL40/2963.
Fatty acid uptake assay
Assay for fatty acid uptake was performed using red 
fluorescence-labelled BODIPY [57].  The fluorescence 
intensity from cells before and 30 minutes after adding 
BODIPY was measured to determine fatty acid uptake. 
In inhibition and competition experiments, different 
concentrations of unlabelled lead compound SBFI26 (50–
200 µM) with the same concentration of labelled BODIPY 
were added directly to the highly malignant PC3-M cells.
Statistical analysis
Student’s t-test was carried out using GraphPad Prism 
software to compare the differences of the means between 
control and experimental groups. All in vitro experiments 
were conducted in triplicate and repeated at least three 
times. The difference is regarded as significant when 
p < 0.05; in the results, p value is represented by asterisks 
as follows:  *P < 0.05; **P < 0.001; ***P < 0.0001.
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